The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression

• Published in: Clinical and translational radiation oncology 2018-06, Vol.11, p.19-25
• Main Authors: Schultz, Helga, Pedersen-Bjergaard, Ulrik, Jensen, Andreas Kryger, Engelholm, Svend Aage, Kristensen, Peter Lommer
• Format: Article
• Language: English
• Subjects: Glucocorticoid induced diabetes; Metastatic spinal cord compression; Survival
• ISSN: 2405-6308; 2405-6308
• DOI: 10.1016/j.ctro.2018.04.004

The influence of glucocorticoid induced hyperglycemia on survival in patients with metastatic spinal cord compression (MSCC) is unknown. In a prospective, observational cohort study 131 patients with MSCC referred to radiotherapy, 30 Gray (Gy) in 10 fractions, and treated with ≥100 mg prednisolone a day were followed with daily blood glucose measurements during radiotherapy. During follow-up a total of 56 patients 43% (95% CI = 35–52%) presented plasma glucose values diagnostic of diabetes. Sixteen patients who developed diabetes were treated with insulin, 12% (95% CI = [6%; 18%]) of the total population. The patients developing diabetes with need for insulin therapy during glucocorticoid therapy had a significantly increased mortality compared to those with normal glucose metabolism and with diabetes without need for therapy, hazard ratio = 2.1 (95% CI = 1.08–4.09, p = 0.0285). To our knowledge this is the first prospective study to describe the influence of glucocorticoid induced diabetes on survival in patients with MSCC from different primary tumors. The results indicate that development of diabetes during high-dose glucocorticoid therapy needing insulin treatment in patients with MSCC from different primary tumors is associated with reduced survival.